# Fruquintinib in the Cross-line Treatment of Refractory mCRC

> **NCT06099314** · — · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 36 (estimated)

## Conditions studied

- Fruquintinib
- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib+PD-1 inhibitors
- **DRUG:** Fruquintinib+TAS-102

## Key facts

- **NCT ID:** NCT06099314
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099314, "Fruquintinib in the Cross-line Treatment of Refractory mCRC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06099314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*